Serologicals Corporation Announces Completion of Acquisition of Cytomyx Ltd.
March 31 2006 - 10:23AM
Business Wire
Serologicals Corporation (NASDAQ: SERO) announced today that it has
completed its previously announced acquisition of Cytomyx Ltd., a
wholly owned subsidiary of Cytomyx Holdings Plc (AIM: CYX). Based
in Cambridge, U.K., Cytomyx Ltd. is a leading provider of ion
channel cell lines and drug discovery services. With 23 distinct
ion channel cell lines commercially available, and more in its
pipeline, Cytomyx Ltd. offers the largest portfolio of distinct ion
channel cell lines in the marketplace today. Serologicals paid U.S.
$7 million for the stock of Cytomyx Ltd. "We are very pleased to
announce the completion of the Cytomyx Ltd. acquisition," said
David A. Dodd, President and CEO of Serologicals. "Ion channels
represent the third largest target class for Biopharma research and
drug development today. The expertise that Cytomyx Ltd. brings will
greatly enhance our drug discovery products and services portfolio
with therapeutically relevant ion channel cell lines and ion
channel screening services. With GPCRs, kinases, and ion channels,
Serologicals will better serve the needs of our Biopharma customers
through a comprehensive portfolio offering." Additional details
about the acquisition and Cytomyx Ltd. business can be found in the
Company's March 14, 2006 press release (www.serologicals.com) in
which the signing of the acquisition agreement was announced.
Serologicals Corporation, headquartered in Atlanta, Georgia, is a
global provider of biological products and enabling technologies,
which are essential for the research, development and manufacturing
of biologically based life science products. The Company's products
and technologies are used in a wide variety of innovative
applications within the areas of oncology, hematology, immunology,
cardiology and infectious diseases, as well as in the study of
molecular biology. Serologicals has approximately 1,000 employees
worldwide, and its shares are traded on the NASDAQ national stock
market under the symbol SERO. For information on Serologicals
Corporation, visit the company's corporate website at
www.serologicals.com. This release contains certain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Words or phrases such as "should result," "are
expected to," "we anticipate," "we estimate," "we project" or
similar expressions are intended to identify forward-looking
statements. These statements are subject to certain risks and
uncertainties that could cause actual results to differ materially
from those expressed in any forward-looking statements. You should
not place undue reliance on forward-looking statements, since the
statements speak only as of the date that they are made, and
Serologicals undertakes no obligation to update these statements
based on events that may occur after the date of this press
release.
Serologicals (NASDAQ:SERO)
Historical Stock Chart
From Sep 2024 to Oct 2024
Serologicals (NASDAQ:SERO)
Historical Stock Chart
From Oct 2023 to Oct 2024